Volastra Therapeutics
Volastra - Short Circuiting Cancer's Chaos
- Headquarters
- New York City, New York
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Website
- volastratx.com
- Total Funding
- $134.1M
- Last Round
- $30.1M Series BSep 2025
- Rounds
- 3
About
Volastra Therapeutics is a clinical-stage oncology biotech company based in New York City, pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN). Founded by Lewis Cantley, Olivier Elemento, and Samuel Bakhoum, Volastra is advancing a synthetic lethal and immune-activating pipeline including two KIF18A inhibitors currently in Phase 1 clinical trials.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sep 2025
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...